In the past week, JAGX stock has gone up by 21.78%, with a monthly gain of 16.31% and a quarterly surge of 1.24%. The volatility ratio for the week is 8.89%, and the volatility levels for the last 30 days are 8.23% for Jaguar Health Inc The simple moving average for the past 20 days is 15.22% for JAGX’s stock, with a -64.34% simple moving average for the past 200 days.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
The 36-month beta value for JAGX is also noteworthy at 0.77. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAGX is 9.99M, and at present, short sellers hold a 7.86% of that float. The average trading volume of JAGX on February 19, 2025 was 426.93K shares.
JAGX) stock’s latest price update
Jaguar Health Inc (NASDAQ: JAGX) has experienced a rise in its stock price by 11.10 compared to its previous closing price of 0.90. However, the company has seen a gain of 21.78% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-18 that Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) and Jaguar family company Napo Pharmaceuticals (“Napo”) today announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo’s plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher (“TDPRV”) from the U.S. Food and Drug Administration (“FDA”) for this indication. With the sunset of the FDA’s Rare Pediatric Disease PRV program in December 2024, and the sunset of the FDA’s Medical Countermeasures PRV Program in October 2023, the TDPRV Program is currently the FDA’s only active PRV program – so there will possibly be fewer PRVs available for purchase, which could increase the value of TDPRVs, spurring increased interest and investment in tropical diseases.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at 5.63% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.37% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 8.89%, as shares surge +18.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.01% lower at present.
During the last 5 trading sessions, JAGX rose by +21.78%, which changed the moving average for the period of 200-days by -92.24% in comparison to the 20-day moving average, which settled at $0.8677. In addition, Jaguar Health Inc saw -1.01% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.85 for the present operating margin
- 0.69 for the gross margin
The net margin for Jaguar Health Inc stands at -3.6. The total capital return value is set at -0.77. Equity return is now at value -432.40, with -72.69 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -0.85. The debt to equity ratio resting at 2.52. The interest coverage ratio of the stock is -34.76.
Currently, EBITDA for the company is -33.13 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 3.25. The receivables turnover for the company is 8.02for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
In summary, Jaguar Health Inc (JAGX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
